seed
Stage
2021
Founded
2
Investors
About
Commit Biologics is a biotechnology company that develops a novel immunotherapy platform called BiCE™, which activates the complement system to selectively kill cancer cells and immune cells involved in autoimmune diseases using bispecific antibodies that bind to the complement protein C1q.
Explore Commit Biologics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.